The companies predict that the partnership will aid diagnoses and drive efficiency in laboratories. Image credit: Proscia.

Germany-based Mindpeak, a provider of artificial intelligence (AI) for pathology, will partner with US-based digital and computational pathology solutions provider Proscia to broaden access to improved diagnosis for cancer patients.

Through the partnership, the companies hope to deliver closely integrated AI-powered workflows, supporting pathologists to make more efficient, informed, and reproducible clinical decisions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Digital pathology incorporates the acquisition, management, sharing and interpretation of pathology information, including slides and data, in a digital environment. Digital slides are created when glass slides are scanned to provide a high-resolution digital image that can be viewed on a computer screen or mobile device.

Digital pathology is used increasingly by laboratories for precision medicine. When combined with AI, the technology can aid pathologists in making diagnoses and drive efficiency in the laboratory.

The newly announced partnership brings together Mindpeak’s CE-IVD algorithms for immunohistochemistry quantification with Proscia’s CE-IVDR Concentriq Dx software platform.

Mindpeak’s AI solutions automatically detect and measure the presence of several biomarkers. Its breast cancer cell detection software, BreastIHC, received the CE-IVD mark in 2021. The software can quantify breast cancer cells for primary diagnosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mindpeak founder and CEO Felix Faber said: “Leading laboratories rely on Proscia’s Concentriq Dx because it offers the robust functionality needed to achieve fully digital diagnosis and is designed to seamlessly incorporate state-of-the-art AI into day-to-day operations. Our integrated solution will enable us to assist a larger number of pathologists and improve outcomes for even more patients.”

Concentriq Dx is an open digital pathology platform, designed to integrate AI applications from Proscia, its customers, and third parties, including Mindpeak, into routine workflows so that laboratories can realise the full potential of pathology’s computational future at scale.

In March 2023, multispeciality, physician-owned healthcare practice Spectrum Healthcare Partners selected the Concentriq Dx software platform to transition its operations to digital pathology at scale.

Proscia’s strategic alliances head Stephan Fromme said: “Proscia has pioneered an open approach to digital pathology because we believe it is the only way that laboratories can drive a complete transformation of their practice.

“Mindpeak’s IHC quantification algorithms are already helping pathologists to make faster, more informed decisions in clinical routine in the USA and the EU to advance the quest for precision medicine. We are looking forward to incorporating them into our ecosystem through this partnership.”